Payment overview · 2025
General Payments
$915.20
47 reported records · 17 companies
Healthcare provider profile · identity verified
Scott Bradley Argo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FORT PAYNE, AL · NPI 1285963421
Verified facts
What the public records show
CMS Open Payments records show Scott Bradley Argo, M.D. received $915.20 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.19 | 21.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.79 | 13.1% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $90.81 | 9.9% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $83.67 | 9.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.47 | 7.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.72 | 7.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.37 | 5.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.93 | 3.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.24 | 3.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.67 | 3.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.53 | 3.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.65 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.78 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.05 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.77 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.93 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $915.20 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.93 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $133.65 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $90.81 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $83.67 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.62 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $72.47 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.72 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $50.73 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.37 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.53 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 220 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 196 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 261 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
154 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
196 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
196 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
261 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
123 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1080 | 168 |
| Gabapentin | Gabapentin | 920 | 154 |
| Lisinopril | Lisinopril | 721 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 629 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 598 | 127 |
| Omeprazole | Omeprazole | 558 | 135 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 549 | 64 |
| Metformin Hcl | Metformin Hcl | 492 | 125 |
| Potassium Chloride | Potassium Chloride | 460 | 139 |
| Pantoprazole Sodium | Pantoprazole Sodium | 443 | 115 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 419 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 111 |
| Tizanidine Hcl | Tizanidine Hcl | 413 | 70 |
| Clonazepam | Clonazepam | 403 | 61 |
| Furosemide | Furosemide | 400 | 127 |
| Pregabalin | Pregabalin | 390 | 63 |
| Montelukast Sodium | Montelukast Sodium | 377 | 86 |
| Doxycycline Hyclate | Doxycycline Hyclate | 348 | 219 |
| Simvastatin | Simvastatin | 339 | 75 |
| Meloxicam | Meloxicam | 331 | 96 |
| Methylprednisolone | Methylprednisolone | 322 | 209 |
| Glimepiride | Glimepiride | 306 | 71 |
| Lorazepam | Lorazepam | 290 | 40 |
| Carvedilol | Carvedilol | 285 | 75 |
| Alprazolam | Alprazolam | 264 | 38 |
| Losartan Potassium | Losartan Potassium | 262 | 67 |
| Trazodone Hcl | Trazodone Hcl | 262 | 81 |
| Mounjaro | Tirzepatide | 261 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 254 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 246 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 56 |
| Eliquis | Apixaban | 220 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 209 | 44 |
| Famotidine | Famotidine | 207 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 57 |
| Jardiance | Empagliflozin | 196 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 193 | 44 |
| Tramadol Hcl | Tramadol Hcl | 193 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 51 |
| Sertraline Hcl | Sertraline Hcl | 185 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 184 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 171 | 45 |
| Prednisone | Prednisone | 170 | 99 |
| Buspirone Hcl | Buspirone Hcl | 168 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 41 |
| Ozempic | Semaglutide | 158 | 32 |
| Farxiga | Dapagliflozin Propanediol | 154 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 149 | 31 |
| Diazepam | Diazepam | 145 | 20 |
| Celecoxib | Celecoxib | 139 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 137 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 131 | 23 |
| Trulicity | Dulaglutide | 123 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 34 |
| Amoxicillin | Amoxicillin | 107 | 74 |
| Methocarbamol | Methocarbamol | 107 | 25 |
| Warfarin Sodium | Warfarin Sodium | 105 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 102 | 30 |
| Allopurinol | Allopurinol | 100 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 28 |
| Memantine Hcl | Memantine Hcl | 97 | 31 |
| Ondansetron Odt | Ondansetron | 96 | 39 |
| Eszopiclone | Eszopiclone | 94 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 93 | 24 |
| Spironolactone | Spironolactone | 89 | 22 |
| Bupropion Xl | Bupropion Hcl | 86 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 21 |
| Alendronate Sodium | Alendronate Sodium | 81 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 81 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 26 |
| Aripiprazole | Aripiprazole | 79 | 19 |
| Januvia | Sitagliptin Phosphate | 79 | 17 |
| Fluconazole | Fluconazole | 78 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 19 |
| Topiramate | Topiramate | 76 | 17 |
| Ibuprofen | Ibuprofen | 74 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 55 |
| Sucralfate | Sucralfate | 73 | 19 |
| Myrbetriq | Mirabegron | 70 | 14 |
| Linzess | Linaclotide | 68 | 16 |
| Meclizine Hcl | Meclizine Hcl | 64 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 63 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 37 |
| Ezetimibe | Ezetimibe | 59 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 15 |
| Synthroid | Levothyroxine Sodium | 58 | 15 |
| Estradiol | Estradiol | 56 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 13 |
| Lovastatin | Lovastatin | 52 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 36 |
| Mirtazapine | Mirtazapine | 50 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 50 | suppressed |
| Glipizide | Glipizide | 49 | 16 |
| Olanzapine | Olanzapine | 49 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 14 |
| Valsartan | Valsartan | 47 | 11 |
| Metformin Hcl Er | Metformin Hcl | 46 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Torsemide | Torsemide | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 11 |
| Cephalexin | Cephalexin | 42 | 28 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Cefdinir | Cefdinir | 41 | 36 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 14 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Promethazine Hcl | Promethazine Hcl | 38 | 17 |
| Temazepam | Temazepam | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 12 |
| Naproxen | Naproxen | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 33 |
| Atenolol | Atenolol | 33 | 11 |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 29 | 26 |
| Nystatin | Nystatin | 29 | 19 |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Baclofen | Baclofen | 24 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Ciclopirox | Ciclopirox | 22 | 19 |
| Lagevrio (Eua) | Molnupiravir | 22 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 14 |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Colchicine | Colchicine | 20 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 11 |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 16 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 12 |
| Digoxin | Digoxin | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Pindolol | Pindolol | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $915.20 · 47 records | Novo Nordisk Inc | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 3, GEMTESA, General - Pain Management, IBSRELA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, Wegovy, XIFAXAN, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error